Search Results - "Bloem, Karien"

Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context by Bloem, Karien, Hernández-Breijo, Borja, Martínez-Feito, Ana, Rispens, Theo

“…One of the factors that may impact drug levels of therapeutic antibodies in patients is immunogenicity, with potential loss of efficacy. Nowadays, many…”
Get full text

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay by Berkhout, Lea C, l'Ami, Merel J, Ruwaard, Jill, Hart, Margreet H, Heer, Pleuni Ooijevaar-de, Bloem, Karien, Nurmohamed, Michael T, van Vollenhoven, Ronald F, Boers, Maarten, Alvarez, Daniel F, Smith, Catherine H, Wolbink, Gerrit J, Rispens, Theo

“…Patients with rheumatoid arthritis (RA) can be successfully treated with tumor necrosis factor (TNF) inhibitors, including the monoclonal antibody adalimumab…”
Get more information

Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I by Horrevorts, Sophie K, Duinkerken, Sanne, Bloem, Karien, Secades, Pablo, Kalay, Hakan, Musters, René J, van Vliet, Sandra J, García-Vallejo, Juan J, van Kooyk, Yvette

“…DC-SIGN is an antigen uptake receptor expressed on dendritic cells (DCs) with specificity for glycans present on a broad variety of pathogens and is capable of…”
Get full text

Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain by Bloem, Karien, Vuist, Ilona M, van der Plas, Arend-Jan, Knippels, Léon M J, Garssen, Johan, García-Vallejo, Juan J, van Vliet, Sandra J, van Kooyk, Yvette

“…C-type lectins are innate receptors expressed on antigen-presenting cells that are involved in the recognition of glycosylated pathogens and…”
Get full text

Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study by Pan, Shan, Tsakok, Teresa, Dand, Nick, Lonsdale, Dagan O., Loeff, Floris C., Bloem, Karien, Vries, Annick, Baudry, David, Duckworth, Michael, Mahil, Satveer, Pushpa‐Rajah, Angela, Russell, Alice, Alsharqi, Ali, Becher, Gabrielle, Murphy, Ruth, Wahie, Shyamal, Wright, Andrew, Griffiths, Christopher E.M., Reynolds, Nick J., Barker, Jonathan, Warren, Richard B., David Burden, A., Rispens, Theo, Standing, Joseph F., Smith, Catherine H., Benham, Marilyn, Evans, Ian, Hussain, Sagair, Kirby, Brian, Lawson, Linda, Mason, Kayleigh, McElhone, Kathleen, Ormerod, Anthony, Owen, Caroline, Barnes, Michael R., Di Meglio, Paola, Emsley, Richard, Evans, Andrea, Payne, Katherine

“…Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real‐world psoriasis…”
Get full text

Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients by Teresa, Jurado, Chamaida, Plasencia-Rodríguez, Ana, Martínez-Feito, Victoria, Navarro-Compán, Theo, Rispens, Annick, Vries, Karien, Bloem, Eva-María, Olariaga, Cristina, Diego, Alejandro, Villalba, Diana, Peiteado, Laura, Nuño, Maria-Gema, Bonilla, Alejandro, Balsa, Dora, Pascual-Salcedo

“…The Infliximab, has proven effective in treating rheumatoid arthritis (RA). A good clinical response is usually associated with high serum drug levels…”
Get full text

Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence by van Strien, Jolinde, Dijk, Lisanne, Atiqi, Sadaf, Schouten, Rogier, Bloem, Karien, Wolbink, Gerrit Jan, Loeff, Floris, Rispens, Theo

“…Accurate anti-drug antibody (ADA) measurements in patient sera requires dissociation of ADA-drug complexes combined with sensitive and specific ADA detection…”
Get full text

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study by Wilkinson, Nina, Tsakok, Teresa, Dand, Nick, Bloem, Karien, Duckworth, Michael, Baudry, David, Pushpa-Rajah, Angela, Griffiths, Christopher E.M., Reynolds, Nick J., Barker, Jonathan, Warren, Richard B., Burden, A. David, Rispens, Theo, Stocken, Deborah, Smith, Catherine

“…Biologics have transformed management of inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by circulating drug levels has…”
Get full text

Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies by Rispens, Theo, Kuijpers, Taco W, Killestein, Joep, van Kempen, Zoé L E, Bloem, Karien

“…One reason for a lack of response to rituximab as well as infusion-related anaphylactic adverse events is the development of antidrug Abs to rituximab. Besides…”
Get full text

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients by Bloem, Karien, van Leeuwen, Astrid, Verbeek, Gerrit, Nurmohamed, Michael T., Wolbink, Gerrit Jan, van der Kleij, Desiree, Rispens, Theo

“…Drug interference complicates assessment of immunogenicity of biologicals and results in an underestimation of anti-drug antibody (ADA) formation…”
Get full text

Capillary Blood Microsampling to Determine Serum Biopharmaceutical Concentration: Mitra ® Microsampler vs Dried Blood Spot by Bloem, Karien, Schaap, Tiny, Boshuizen, Ronald, Kneepkens, Eva L, Wolbink, Gerrit J, Vries, Annick de, Rispens, Theo

Get full text

Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab by Wientjes, Maike H M, Gijzen, Titia M G, den Broeder, Nathan, Bloem, Karien, de Vries, Annick , van den Bemt, Bart J F, den Broeder, Alfons A, Verhoef, Lise M

“…Abstract Objectives The REDO trial (REtreatment with Rituximab in RhEumatoid arthritis: Disease Outcome after Dose Optimisation) showed that ultra-low-dose…”
Get full text

Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis by Toorop, Alyssa A, Hogenboom, Laura, Bloem, Karien, Kocyigit, Merve, Commandeur, Nadine W M, Wijnants, Anne, Lissenberg-Witte, Birgit I, Strijbis, Eva M M, Uitdehaag, Bernard M J, Rispens, Theo, Killestein, Joep, van Kempen, Zoé L E

“…BackgroundThe majority of patients with multiple sclerosis on ocrelizumab have B-cell depletion after standard interval dosing of 26 weeks. With B-cell-guided…”
Get full text

Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti‐adalimumab in patients with inflammatory diseases by Kneepkens, Eva L., Pouw, Mieke F., Wolbink, Gerrit Jan, Schaap, Tiny, Nurmohamed, Michael T., Vries, Annick, Rispens, Theo, Bloem, Karien

“…Aims Development of a self‐sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and…”
Get full text

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation by Berends, Sophie E., D'Haens, Geert R. A. M., Schaap, Tiny, Vries, Annick, Rispens, Theo, Bloem, Karien, Mathôt, Ron A. A.

“…Aims Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay…”
Get full text

Mo1856 - Clinical Feasibility of Dried Blood Sampling for Infliximab in IBD-Patients by Berends, Sophie E., D'Haens, Geert R., Bloem, Karien, Schaap, J, de Vries, Annick, Rispens, Theo, Mathot, Ron

Get full text

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis by Kempen, Zoé L. E., Hogenboom, Laura, Toorop, Alyssa A., Steenhuis, Maurice, Stalman, Eileen W., Kummer, Laura Y. L., Dam, Koos P. J., Bloem, Karien, Brinke, Anja, Ham, S. Marieke, Kuijpers, Taco W., Wolbink, Gerrit J., Loeff, Floris C., Wieske, Luuk, Eftimov, Filip, Rispens, Theo, Strijbis, Eva M. M., Killestein, Joep

“…Ocrelizumab, an anti‐CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome‐coronavirus 2…”
Get full text

Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial by Jacobse, Justin, Voorde, Wouter, Tandon, Anushka, Romeijn, Stefan G., Grievink, Hendrika W., Maaden, Koen, Esdonk, Michiel J., Moes, Dirk Jan A.R., Loeff, Floris, Bloem, Karien, Vries, Annick, Rispens, Theo, Wolbink, Gertjan, Kam, Marieke, Ziagkos, Dimitrios, Moerland, Matthijs, Jiskoot, Wim, Bouwstra, Joke, Burggraaf, Jacobus, Schrier, Lenneke, Rissmann, Robert, Cate, Rebecca

“…Aims To evaluate feasibility of intradermal (i.d.) adalimumab administration using hollow microneedles, and to compare a single i.d. dose of adalimumab using a…”
Get full text

Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients by Zijlstra, Marieke, Jongsma, Maria M.E., Vries, Annick, Schaap, Tiny, Bloem, Karien, Ridder, Lissy

“…ABSTRACT Objectives: Blood to measure infliximab (IFX) levels is typically obtained with venipuncture. Dried blood sampling (DBS), using capillary blood…”
Get full text

Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells by García-Vallejo, Juan J., Ambrosini, Martino, Overbeek, Annemieke, van Riel, Wilhelmina E., Bloem, Karien, Unger, Wendy W.J., Chiodo, Fabrizio, Bolscher, Jan G., Nazmi, Kamran, Kalay, Hakan, van Kooyk, Yvette

“…► Multivalent antigen presentation improves delivery through DC-SIGN. ► 16–32 glycan units are the optimal multivalency for DC-SIGN targeting. ► DC-SIGN…”
Get full text